Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia
Clinical trial NCT05563545 · COMPLETED
Trial details
- NCT number
- NCT05563545
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-21
- Primary completion
- 2022-11-25
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.